PATENT CLAIM ANALYSIS

Application Number: 15907619
Application Type: Utility
Filing Date: 2018-02
Publication Date: 2018-07
Patent Classification: ["514", "234200"]

Abstract:
Provided herein are methods for treating or preventing a cancer, comprising administering an effective amount of a Dihydropyrazino-Pyrazine Compound and an effective amount of an androgen receptor antagonist to a patient having a cancer.

Claim (Index 1):
A method for achieving complete response, partial response or stable disease, as determined by the Response Evaluation Criteria in Solid Tumors (RECIST 1.1), in a patient having castration-resistant prostate cancer, comprising administering to a patient having castration-resistant prostate cancer an effective amount of a Dihydropyrazino-Pyrazine Compound in combination with an effective amount of MDV3100, wherein the Dihydropyrazino-Pyrazine Compound is a compound having the structure: or a pharmaceutically acceptable salt, clathrate, solvate, stereoisomer, tautomer or isotopologue thereof.

Metadata:
- Claim Count in Document: 17.0
- Percentile: 88.0
- Lexical Diversity: 1.33333
- Patent Class: 514.0
- Transitional Phrase Type: open
- Component Type: 1
- Foreign Priority: False
- Related Applications: ['14254017', '15299589', '14254004', '15459111', '14254020']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.7846485653767703
- 35 USC 102 Novelty (BERT): 0.6321694654310342
- Combined Prediction Score: 0.7694006553821967
- Mean Citation Score: 412.79469
- Max Citation Score: 586.8324
- Similarity Product: 565.583408361411

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 0
- Claim Label 112: 1
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test